IDEX Corporation delivered solid fourth quarter and full-year 2025 results, characterized by organic sales growth of 1% and a 40 basis point expansion in adjusted EBITDA margin. The standout performance was in the Health, Science, and Technology (HST) segment, which drove a 16% increase in total organic orders, with HST specifically surging 34% to a record $493 million, fueled by AI-related data center demand and semiconductor strength. Full-year free cash flow remained robust at $617 million, supporting nearly $250 million in share repurchases. For 2026, management guides for conservative organic growth of 1% to 2% and adjusted EPS of $8.15 to $8.35, reflecting confidence in HST momentum but caution regarding persistent softness in industrial and chemical end markets.
| Metric | Value | Change |
|---|---|---|
| Q4 Organic Sales Growth | 1% | N/A |
| Q4 Organic Orders Growth | 16% | N/A |
| HST Q4 Orders Growth | 34% | N/A |
| Q4 Adjusted EBITDA Margin | Up 40 bps YoY | +40 bps |
| FY 2025 Free Cash Flow | $617 million | +2% |
| FY 2025 FCF Conversion | 103% | N/A |
| FY 2025 Share Repurchases | $250 million | N/A |
IDEX is successfully leveraging its '8020' strategy to capture significant demand in the AI ecosystem. The HST segment saw 34% organic order growth, driven by pneumatics for liquid cooling and optics for switching. Management noted, 'Our performance pneumatics group... are collaborating with thermal management applications to support data center liquid cooling,' positioning IDEX as a critical enabler of AI infrastructure expansion. This strategic pivot is diversifying revenue away from cyclicals and into higher-growth secular markets.
The company maintains a robust capital deployment strategy, balancing M&A, buybacks, and dividends. In 2025, IDEX repurchased nearly $250 million in shares and paid $213 million in dividends. CFO Sean Gillen indicated a continued 'base amount of repurchase' around $75 million per quarter, signaling confidence in cash generation and a commitment to returning value to shareholders while maintaining an investment-grade rating.
The '8020 playbook' remains central to IDEX's operational strategy, driving margin expansion (40 bps in Q4) by focusing resources on the most profitable 20% of products and customers. This focus allows for a 'flywheel effect' where gains in advantaged areas like HST fund further simplification and margin improvement in other segments. Management emphasized that this resource allocation is key to sustaining growth even in a flat macro environment.
Following the acquisition of Microlam, IDEX is prioritizing integration over large transformative deals. Management stated that 'new acquisitions will likely be bolt-on in nature,' focusing on absorbing recent purchases to drive immediate margin and growth synergies. This disciplined approach to M&A reduces integration risk and allows for the application of the IDEX operating model to newly acquired entities to boost margins quickly.
Despite a recent uptick in PMI, IDEX has not seen an inflection in demand for its industrial-facing businesses (FMT, FSDP). Orders in chemical, energy, and agriculture markets remain 'subdued,' and management admitted, 'we are not seeing an inflection point and activity.' This persistent weakness in industrial end markets caps near-term growth potential for a significant portion of the portfolio and validates the conservative 1-2% growth guidance.
The Fire & Safety Diversified Products (FSDP) segment struggled, with organic sales declining 5% in Q4. Management cited 'pressures outside The US' and 'cyclical softness in dispensing,' indicating that this segment remains a drag on overall performance. The lack of visibility for a recovery in FSDP, combined with margin pressure in FMT, suggests that the company's industrial exposure remains a vulnerability until the macro environment improves.
Pricing power, which supported margins in 2025 (approx. 3.5%), is expected to wane in 2026, dropping to 1-2%. This reduction in price tailwinds, combined with volume deleverage in weaker segments, creates a tighter margin environment where operational efficiency must do the heavy lifting to meet the 26-27% EBITDA margin guidance. Any failure to realize projected productivity gains could result in margin shortfalls.
Growth in the Life Sciences platform has moderated to 'low single-digit,' impacted by government shutdowns and uncertainty around NIH funding. While stable, this key historical growth driver is not currently providing the momentum seen in the company's newer tech-focused platforms. Management noted that 'open questions still remain' regarding China and academic research funding, adding a layer of uncertainty to this segment's outlook.
Overall: Management exhibited a disciplined and confident demeanor, particularly regarding the strategic pivot to high-growth markets like data centers and semiconductors. CEO Eric Ashleman was pragmatic about macro headwinds but enthusiastic about the '8020' strategy's effectiveness, while new CFO Sean Gillen projected stability and financial rigor, emphasizing capital allocation discipline.
Confidence: HIGH - Management cited record order books ($493M in HST) and specific wins in AI infrastructure to back their optimism. Their confidence is anchored in the visibility provided by these strong orders, despite conservative guidance for the broader portfolio.
1% to 2%
26% to 27%
$8.15 to $8.35
~1%
$1.73 to $1.78
Hedging & Uncertainty: Management employed hedging language primarily regarding the timing of the industrial recovery. Phrases like 'if there is a return to growth,' 'likely,' and 'should it occur' were used to describe the macro outlook. This suggests that while they are prepared for an upturn, they are not banking on it in their guidance. They also hedged on the sustainability of Q4 orders, noting some 'year-end budget flush' but emphasizing underlying momentum. For example, Eric Ashleman stated, 'Made more likely if last year's volatile policy headwinds moderate,' indicating dependence on external factors beyond their control.
We are not seeing an inflection point and activity, and our guidance reflects this reality. - Eric Ashleman, President and CEO
We can chase it without frankly, adding anything to the resource of the capital base. - Eric Ashleman, President and CEO
Our 8020 playbook... supports the formal resource choices in segmentation to drive growth. - Eric Ashleman, President and CEO
We expect organic growth of 1% to 2%. - Sean Gillen, Chief Financial Officer
There is certainly chatter around the likelihood... But haven't seen it yet. - Eric Ashleman, President and CEO
Analyst Sentiment: Analysts were probing for confirmation of a macro turnaround, specifically asking about the disconnect between strong HST orders and the sluggish industrial outlook. There was skepticism about whether the PMI uptick would translate to IDEX's business immediately, with questions focused on the sustainability of order growth and the timing of revenue conversion.
Management Responses: Management was firm in their 'wait and see' approach regarding the macro, emphasizing their 'rapid replenishment' business model means they will see the turn when it happens, but it hasn't happened yet. They were expansive on the specifics of data center exposure and capital allocation, using the platform to reinforce the validity of their strategic pivot.
Discussion on the disconnect between strong orders (HST) and sales conversion, with management explaining longer lead times for data center projects.
Inquiries into the sustainability of pricing power, with management guiding for a decrease from ~3.5% to 1-2% in 2026.
Questions on capital allocation priorities, specifically regarding share repurchases and M&A, with management confirming a focus on bolt-ons and steady buybacks (~$75M/quarter).
Deep dive into specific end markets like Life Sciences and Lithography, where management highlighted stability but noted government funding headwinds.
IDEX is successfully executing a strategic pivot toward high-growth, advantaged markets (AI, semiconductors, life sciences), evidenced by record HST orders and margin expansion. The company's disciplined capital allocation and '8020' operational rigor provide downside protection and support steady compounding. However, the conservative 1-2% growth guidance reflects real pressure in industrial and chemical end markets (FMT/FSDP), which comprise a significant portion of revenue. Until a broad industrial recovery materializes to complement the HST strength, the stock is likely to remain range-bound, making a HOLD rating appropriate while the growth story matures.
Management noted that despite PMI moving above 50, they have 'not seen an inflection point' in activity. Orders in chemical, energy, and agriculture remain subdued, suggesting the industrial recession is persisting longer than hoped.
IDEX is experiencing a 'strongest mark' in orders driven by AI data center build-outs. Demand is coming from liquid cooling, on-site power generation, and semiconductor memory production, indicating a durable secular tailwind.
Municipal water-facing businesses grew mid-single digits, supported by increased capital spending for infrastructure refurbishment and the critical nature of IDEX's diagnostic technologies.
The prolonged government shutdown in Q4 created pressure on academic research and life sciences segments, adding uncertainty to the 2026 outlook for these specific areas.